Business
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
(TheNewswire) Toronto, Ontario – TheNewswire - 9 September 2025 –...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Toronto, Ontario –\n \n\n TheNewswire -\n \n\n 9 September 2025\n \n\n –\nHelix BioPharma Corp.\n \n\n (TSX:\n“HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”)\n \n\n (\n \n\n “Helix”\n \n\n or the\n \n\n “Company”\n \n\n ), a\nclinical-stage oncology company shaping a near future where today’s\nhard-to-treat cancers are vincible, is pleased to announce that the\nCompany will present at the\n \n\n Q3\n2025\n \n\n Investor Summit\nVirtual\n \n\n (\n \n\n “Investor Summit”\n \n\n ) on September 16,\n2025.\n \n\n\n\n The Investor Summit is an exclusive, quarterly virtual\nevent for investors specializing in small and microcap stocks. Running\nfrom September 16 to 17, this quarter’s event emphasizes\n \n\n undervalued\n \n\n MicroCap companies with strong growth\ncatalysts\n \n\n . Helix will use the occasion to\nhighlight its ongoing preparation for a Phase Ib/Randomized Phase II\nclinical study of L-DOS47 in combination with pembrolizumab for the\nfirst-line treatment of non-small cell lung cancer (NSCLC), as well as\nthe Company’s planned uplisting to NASDAQ in Q1 2026. Together,\nthese upcoming milestones reflect Helix’s strategy to accelerate\ndevelopment of oncology assets with the potential to turn\nhard-to-treat cancers into manageable conditions, while positioning\nthe Company for broader visibility and access to global capital\nmarkets. In addition to the presentation, investors will have the\nopportunity to book one-on-one meetings with\n \n\n Thomas Mehrling, MD, PhD, CEO\n \n\n of Helix BioPharma\n \n\n ,\nfor direct insight into the Company’s vision and near-term growth\nstrategy.\n \n\n\n\n Event Details:\n \n\n\n\n\n\n Event:\n \n\n Q3 2025\nInvestor Summit\n \n\n\n\n\n\n Presentation Date:\n \n\n September 16, 2:30 PM ET\n \n\n\n\n\n\n Presenter:\n \n\n Thomas Mehrling, MD, PhD, CEO\n \n\n\n\n\n\n Webcast link:\n \n\n\n\n https://investorsummitgroup.com/presentor/q3-track-1-helix-biopharma-corp/\n \n\n\n\n\n\n\n\n Investor registration\n(free):\n \n\n\n\n https://investorsummitgroup.fillout.com/t/8CZGk3gSQbus\n \n\n\n\n\n\n\n\n About Investor Summit Gro...